Cesium-131 Interstitial Brachytherapy for Recurrent Malignancies of Skull Base
20 December 2018
20 February 2019
09 April 2019 (online)
Background Recurrent malignancy of the skull base poses a treatment challenge due to a lack of treatment options and potential for damage to surrounding structures.
Methods Case report of two patients with recurrent nasopharyngeal carcinoma (NPC) of skull base previously treated with adjuvant chemoradiotherapy using intensity-modulated radiation therapy (IMRT).
Results In both cases, the recurrent tumor was treated with endoscopic surgical resection and intraoperative cesium-131 (Cs-131) interstitial brachytherapy (IBT). Total dose delivered to tumor bed was 57 and 60 Gy, respectively. With a half- life of 9 days, the majority of the radiation dose had been delivered within the first 40 days following implant and there have been no treatment-related complications reported.
Conclusion Intraoperative Cs-131 IBT is a feasible adjuvant treatment option for patients with recurrent malignancies of the skull base. These are the first known cases of Cs-131 IBT used for recurrent NPC.
The authors have indicated they have no financial relationships relevant to this article to disclose.
- 1 Kupferman ME, Morrison WH, Santillan AA. , et al. The role of interstitial brachytherapy with salvage surgery for the management of recurrent head and neck cancers. Cancer 2007; 109 (10) 2052-2057
- 2 Parashar B, Wernicke AG, Pavese A. , et al. Cesium-131 permanent seed brachytherapy: dosimetric evaluation and radiation exposure to surgeons, radiation oncologists, and staff. Brachytherapy 2011; 10 (06) 508-513
- 3 Armpilia CI, Dale RG, Coles IP, Jones B, Antipas V. The determination of radiobiologically optimized half-lives for radionuclides used in permanent brachytherapy implants. Int J Radiat Oncol Biol Phys 2003; 55 (02) 378-385